Our newly developed antibodies to CETN1 with minimal cross‐reactivity to CETN2 allowed us to demonstrate for the first time, using tumor microarray analysis which translate the qPCR data into the CETN1 protein expression, by 50% of PDAC tumors, in contrast to non‐expression of CETN1 by normal pancreas. Here, CETN2 is linked to neoplasm.